▸ CM: all received prior anti-PD1 and anti-CTLA4 IMC-F106C was well tolerated Most frequent related AE was Grade 1/2 CRS, consistent with proposed mechanism | --- | --- | --- | --- | |----------------------------------------------|--------------------------------|-----------------------|------------| | Preferred Term (MedDRA v23.1) | 0.3 – 10 mcg † N=18 | 20 – 320 mcg † N=37 | Total N=55 | | All grades events in ≥ 25% of patients , n % | | | | | At least one event | 18 (100) | 34 (92) | 52 (95) | | Pyrexia* ...

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - Chief Executive Officer & Director Ralph Torbay - Head of Commercial Brian Di Donato - Chief Financial Officer & Head of Strategy David Berman - Head of Research & Development Conference Call Participants Michael Yee - Jefferies Patrick Trucchio - H.C. Wainwright Justin Kim - Oppenheimer Justin Zelin - BTIG Peter Lawson - Barclays ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Immunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of £42 million ($51 million) in Q4 2022 and £117 million ($141 million) in 2022; approved in over 30 countries and nearly 200 patients on global early access program Enrolling IMC-F106C (PRAME-HLA-A02) in monotherapy and combination arms of Phase 1/2 clinical trial and expanding PRAME franchise, including first-in-class PRAME-HLA-A24 target and a PRAME HLA-A02 half-life extension IND planned for first- ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|--------------|-------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Patients | Transformative Medicines for | | | | | | | | | | | | | | | | | JANUARY 2023 | | | Forward-looking statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "can," "will," "believe," "ex ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------|---------------|-----------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Science to | | | | | | | | | | Transform Lives | | | | | | | | | | | | | | | | | | | NOVEMBER 2022 | | | Forward-looking statement 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words ...

Exhibit 99.4 Execution Version LOAN AGREEMENT Dated as of November 8, 2022 among IMMUNOCORE LIMITED (as Borrower, and a Credit Party), IMMUNOCORE HOLDINGS PLC (as Parent, and a Credit Party), IMMUNOCORE LLC IMMUNOCORE COMMERCIAL LLC and IMMUNOCORE IRELAND LIMITED (as additional Credit Parties), THE OTHER GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP (as a Lender) TABLE OF CONTENTS | | | Page | | --- | -- ...

#728O Phase 1 dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors Omid Hamid, 1 Takami Sato,2 Diwakar Davar,3 Margaret Callahan,4 Fiona Thistlethwaite,5 Raid Aljumaily,6 Melissa Johnson,7 Hendrik-Tobias Arkenau,8 Ecaterina Dumbrava,9 Benjamin Izar,10 Hui Amy Chen,11 Shannon Marshall,12 Yuan Yuan,12 Mugdha Deo,12 Sarah Stanhope,12 Laura Collins,12 Renee Mundy,12 Shaad Abdullah,12 Juanita Lopez13 1The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Lo ...

IMMUNOCORE Corporate Presentation August 2022 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this pr ...

Immunocore Holdings (NASDAQ:IMCR) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO & Director Brian Di Donato - CFO & Head, Strategy Ralph Torbay - Head, Commercial David Berman - Head, Research & Development Conference Call Participants Michael Yee - Jefferies Jessica Fye - JPMorgan Chase & Co. Tyler Van Buren - Cowen and Company Justin Kim - Oppenheimer Justin Zelin - BTIG Matthew Phipps - William Blair & Company Gil Blum - Ne ...